FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.
What happened
FDA inspected the company's drug manufacturing facility at 13056 Saticoy Street, North Hollywood, CA, from November 18 to 27, 2024. Investigators found the firm did not test incoming ingredients such as glycerin for identity, including the test that detects diethylene glycol (DEG) and ethylene glycol (EG), and relied on supplier certificates of analysis without checking their reliability. FDA also found the water system was not adequately monitored, manufacturing processes were not validated, and the quality unit did not ensure stability testing, annual product reviews, or calibrated lab equipment. The company's December 20, 2024 response was reviewed.
What FDA found
The firm did not test each incoming ingredient for identity, purity, strength, and quality before using it in drug products.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm relied on its suppliers' certificates of analysis without ever establishing that those supplier tests were reliable.
21 CFR 211.84(d)(2)Glycerin and other high-risk ingredients were not tested with the USP identity test that catches diethylene glycol and ethylene glycol, which have caused fatal poisonings.
21 CFR 211.84(d)(1)Water used as an ingredient came from a system that was not adequately monitored or routinely tested to meet USP water specifications.
21 CFR 211.84The firm never validated its manufacturing processes to show they consistently produce drug products meeting their quality attributes.
21 CFR 211.100(a)The quality unit did not ensure an ongoing stability program, at least annual product reviews, or adequate laboratory controls such as calibrated equipment.
21 CFR 211.22
What FDA wants
FDA asks the company to reply in writing within 15 working days describing corrections and preventive actions. The letter also asks for DEG and EG test results from retained samples within 30 calendar days, a risk assessment for unexpired products that may contain at-risk ingredients, a water system remediation plan, and clarification of whether it will resume making drugs for the U.S. market.
Who should pay attention
- brands and retailers that buy finished OTC drugs from this contract manufacturer
- companies buying glycerin or other high-risk ingredients from the same suppliers
- cosmetic brands whose products were made at this facility
This is a summary. Read the original letter on fda.gov.